Insider · CIK 0001385116

Almon Einat Brill

Reports to the SEC for 1 company · CARMIEL, L3

sec.gov

Transactions

Companies

Filings

CIK

0001385116

Forms 4 and 5

Insider transactions

37 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2020-06-07	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)A Award	SVP, Chief Development Officer	AAward	+197K sh	—	—	196,995
2018-09-13	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)A Award	SVP, Chief Development Officer	AAward	+700K sh	—	—	700,000
2015-03-23	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)A Award	SVP, Chief Development Officer	AAward	+250K sh	—	—	250,000
2012-07-16	PLXProtalix BioTherapeutics, Inc.A Award	SVP, Chief Development Officer	AAward	+185K sh	—	—	185,000
2012-05-02	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	−50K sh	—	—	0
2012-05-02	PLXProtalix BioTherapeutics, Inc.M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	+117K sh	$0.97	+$114K	116,848
2012-05-02	PLXProtalix BioTherapeutics, Inc.M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	+50K sh	$2.65	+$133K	166,848
2012-05-02	PLXProtalix BioTherapeutics, Inc.S Sale	SVP, Chief Development Officer	SSale	−167K sh	$7.13	−$1.19M	0
2012-05-02	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	−117K sh	—	—	0
2010-10-06	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	−70K sh	—	—	116,848
2010-10-06	PLXProtalix BioTherapeutics, Inc.S Sale	SVP, Chief Development Officer	SSale	−15K sh	$9.29	−$139K	0
2010-10-06	PLXProtalix BioTherapeutics, Inc.M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	+70K sh	$0.97	+$68K	0
2010-10-05	PLXProtalix BioTherapeutics, Inc.S Sale	SVP, Chief Development Officer	SSale	−20K sh	$9.08	−$182K	0
2010-10-04	PLXProtalix BioTherapeutics, Inc.S Sale	SVP, Chief Development Officer	SSale	−35K sh	$9.02	−$316K	0
2010-09-07	PLXProtalix BioTherapeutics, Inc.M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	+45.3K sh	$0.97	+$44K	0
2010-09-07	PLXProtalix BioTherapeutics, Inc.S Sale	SVP, Chief Development Officer	SSale	−22.5K sh	$8.16	−$184K	0
2010-09-07	PLXProtalix BioTherapeutics, Inc.M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	+4,740 sh	$0.40	+$1,891.26	0
2010-09-07	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	−4,740 sh	—	—	0
2010-09-07	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	−45.3K sh	—	—	186,848
2010-09-03	PLXProtalix BioTherapeutics, Inc.S Sale	SVP, Chief Development Officer	SSale	−27.5K sh	$8.00	−$220K	0
2010-02-25	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)A Award	SVP, Chief Development Officer	AAward	+130K sh	—	—	130,000
2009-10-19	PLXProtalix BioTherapeutics, Inc.M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	+94K sh	$0.40	+$37.5K	0
2009-10-19	PLXProtalix BioTherapeutics, Inc.S Sale	SVP, Chief Development Officer	SSale	−38.3K sh	$9.43	−$361K	0
2009-10-19	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	−94K sh	—	—	4,740
2009-10-19	PLXProtalix BioTherapeutics, Inc.F Tax Payment	SVP, Chief Development Officer	FTax Payment	−3,954 sh	$9.48	−$37.5K	0
2009-10-16	PLXProtalix BioTherapeutics, Inc.S Sale	SVP, Chief Development Officer	SSale	−23.7K sh	$9.39	−$222K	0
2009-10-15	PLXProtalix BioTherapeutics, Inc.S Sale	SVP, Chief Development Officer	SSale	−28K sh	$9.39	−$263K	0
2009-07-07	PLXProtalix BioTherapeutics, Inc.F Tax Payment	SVP, Chief Development Officer	FTax Payment	−4,822 sh	$4.95	−$23.9K	0
2009-07-07	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	−59.8K sh	—	—	98,694
2009-07-07	PLXProtalix BioTherapeutics, Inc.S Sale	SVP, Chief Development Officer	SSale	−11K sh	$4.95	−$54.5K	0
2009-07-07	PLXProtalix BioTherapeutics, Inc.M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	+59.8K sh	$0.40	+$23.9K	0
2009-07-06	PLXProtalix BioTherapeutics, Inc.S Sale	SVP, Chief Development Officer	SSale	−44K sh	$5.13	−$226K	0
2009-05-18	PLXProtalix BioTherapeutics, Inc.S Sale	SVP, Chief Development Officer	SSale	−40K sh	$4.00	−$160K	0
2009-05-18	PLXProtalix BioTherapeutics, Inc.F Tax Payment	SVP, Chief Development Officer	FTax Payment	−4,707 sh	$3.79	−$17.8K	40,000
2009-05-18	PLXProtalix BioTherapeutics, Inc.M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	+44.7K sh	$0.40	+$17.8K	44,707
2009-05-18	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)M Exercise/Conversion	SVP, Chief Development Officer	MExercise/Conversion	−44.7K sh	—	—	158,516
2009-02-25	PLXProtalix BioTherapeutics, Inc. · Stock Options (Right to Buy)A Award	SVP, Chief Development Officer	AAward	+50K sh	—	—	50,000

Recent filings

Accepted (ET)
Jun 84
Almon Einat Brill0001104659-20-070906
SEC(opens sec.gov)
Sep 144
Almon Einat Brill0001144204-18-049522
SEC(opens sec.gov)
May 74
Protalix BioTherapeutics, Inc.0001144204-15-028480
SEC(opens sec.gov)
Jul 184
Almon Einat Brill0001144204-12-039996
SEC(opens sec.gov)
May 44
Almon Einat Brill0001144204-12-026344
SEC(opens sec.gov)
Oct 64
Almon Einat Brill0001209191-10-049624
SEC(opens sec.gov)
Sep 84
Almon Einat Brill0001209191-10-045450
SEC(opens sec.gov)

Companies

Protalix BioTherapeutics, Inc.SVP, Chief Development OfficerPLX

Address

C/O PROTALIX BIOTHERAPEUTICS, INC. 2 SNUNIT STREET, SCIENCE PARK, POB 455

CARMIEL, L3, 20100